The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery

Prada-Villaverde, Arancha; Esquivel, Jesús; Lowy, Andrew M.; Markman, Maurie; Chua, Terence C.; Pelz, Joerg; Baratti, Dario; Baumgartner, Joel M.; Berri, Richard N.; Bretcha-Boix, Pedro; Deraco, Marcello; Flores-Ayala, Guillermo; Gléhen, Olivier; Gómez-Portilla, Alberto; González-Moreno, Santiago; Goodman, Martin; Halkia, Evgenia; Kusamura, Shigeki; Möller, Mecker G.; Passot, Guillaume; Pocard, Marc; Salti, George I.; Sardi, Armando; Senthil, Maheswari; Spiliotis, John; Torres-Melero, J; Turaga, Kiran K.; Trout, Richard

doi:10.1002/jso.23728

Cited by 132 publications

(105 citation statements)

References 15 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…The duration ranges from 30 to 120 minutes (45) and different institutions use different protocols. In our clinic, we use the Sugarbaker protocol (44).…”

Section: Group 6 (Sr + Ca + D)mentioning

confidence: 99%

The Effects of Hyperthermic Intraperitoneal Chemoperfusion on Colonic Anastomosis: An Experimental Study in a Rat Model

Aghayeva

Benlice

Bilgin

et al. 2017

Tumori

View full text Add to dashboard Cite

Introduction Cytoreductive surgery (CRS) with subsequent hyperthermic intraperitoneal chemotherapy (HIPEC) is a promising modality to treat and prevent peritoneal metastases. However, this treatment is associated with signficant morbidity and mortality. Whether or not CRS with HIPEC interferes with anastomotic healing has also been debated. This study was designed to investigate the effects of mitomycin C, cisplatin, oxaliplatin, and doxorubicin used in HIPEC treatment on colonic anastomosis healing in a rat model. Methods Sixty Wistar albino rats were employed in the study. Sigmoid resection and end-to-end colorectal anastomosis was performed in all rats. Group 1 rats underwent the surgical procedure alone, while group 2 rats were given hyperthermic intraperitoneal lavage with heated saline following surgery. Groups 3, 4, 5, and 6 had surgery with concomitant HIPEC treatment with mitomycin C, cisplatin, oxaliplatin, and doxorubicin, respectively. Anastomotic bursting pressures and hydroxyproline levels were evaluated. Results Regarding the hydroxyproline levels, groups 1 and 2 showed significantly higher values than other groups (p<0.001). However, there was no significant difference between the HIPEC treatment groups (groups 3, 4, 5, and 6) (p>0.05). When groups were compared regarding bursting pressure values, no significant differences were observed (p = 0.81). Conclusions This study demonstrated that the HIPEC procedure with mitomycin C, cisplatin, oxaliplatin and doxorubicin had negative effects on hydroxyproline levels, but had no detrimental effect on anastomotic bursting pressure in a rat model.

show abstract

“…The duration ranges from 30 to 120 minutes (45) and different institutions use different protocols. In our clinic, we use the Sugarbaker protocol (44).…”

Section: Group 6 (Sr + Ca + D)mentioning

confidence: 99%

The Effects of Hyperthermic Intraperitoneal Chemoperfusion on Colonic Anastomosis: An Experimental Study in a Rat Model

Aghayeva

Benlice

Bilgin

et al. 2017

Tumori

View full text Add to dashboard Cite

show abstract

“…In one study 72 , a logistic regression analysis comparing oxaliplatin with mitomycin C (corrected for the extent of ptc) revealed nonsignificant hazard ratios for relapse-free survival and os: 1.24 (p = 0.39) and 1.37 (p = 0.32) respectively. In the other study 73 , although median os after complete crs and hipec with mitomycin C (n = 392) or oxaliplatin (n = 155) was not different (32.7 months vs. 31.4 months, p = 0.925), mitomycin C was a statistically more effective agent than oxaliplatin for hipec in colorectal cancer patients with favourable histology and a low burden of disease (median os: 54.3 months vs. 28.2 months, p = 0.012).…”

Section: Colorectal Cancermentioning

confidence: 85%

“…In two recent comparative studies 72,73 , no clear benefit in outcome for hipec with oxaliplatin or with mitomycin C could be demonstrated overall. In one study 72 , a logistic regression analysis comparing oxaliplatin with mitomycin C (corrected for the extent of ptc) revealed nonsignificant hazard ratios for relapse-free survival and os: 1.24 (p = 0.39) and 1.37 (p = 0.32) respectively.…”

Section: Colorectal Cancermentioning

confidence: 97%

Treatment of Peritoneal Surface Malignancies with Hyperthermic Intraperitoneal Chemotherapy—Current Perspectives

2016

View full text Add to dashboard Cite

Peritoneal carcinomatosis (ptc) represents advanced malignant disease and has generally been associated with a grim prognosis. Peritoneal surface malignancy is often the major source of morbidity and mortality; it is of major concern in cancer management. Although ptc is categorized as metastatic disease, it represents a special disease pattern considered to be a locoregional disease limited to the abdominal cavity. The combination of cytoreductive surgery (crs) and intraoperative hyperthermic intraperitoneal chemotherapy (hipec) has successfully been used as locoregional treatment for selected patients with ptc from gastric, colorectal, and ovarian cancer; with mesothelioma; and with pseudomyxoma peritonei. In the prophylactic setting, hipec can also be used to prevent ptc in high-risk patients, and the first results of the "second-look" approach are promising. Patient selection-in which the risks of perioperative morbidity and mortality, which are analogous to those for any other major gastrointestinal surgery, are assessed-is of utmost importance. Those risks have to be weighed against the anticipated survival benefit, which depends mainly on tumour biology, extent of disease, and probability of achieving complete crs. The present review discusses the principles of crs and hipec, the most significant recent clinical data, and current perspectives concerning the application of this treatment modality in various malignancies. Ongoing trials and future directions are noted. It appears that the combination of crs and hipec is an indispensable tool in the oncologist's armamentarium.

show abstract

“…After review of current literature dated till 2014 and using Ovid, Medline and Pubmed search engines, only 4 research articles have been chosen [5][6][7][8]. Two articles were prospective non randomized cohort studies Ceelen W et al [6] and Passot G et al [7], one retrospective study Villaverde et al [5] and one review study Kuijpers A et al [8].…”

Section: Resultsmentioning

confidence: 99%

“…No other factors affect MOS. The only contribution of HIPEC in response rate/ survival was in the type of chemotherapy chosen for HIPEC, so Villaverde et al [5] found that, MOS: 54.3 was months in MMC ( mitomycin group) , and 28.2 months in Oxaliplatin group ( both groups has low volume peritoneal disease) ( Table 1). Passot G et al [7] Prospective Non-Randomised …”

Section: Review Articlementioning

confidence: 99%

Management of Peritoneal Metastases of Colorectal Cancer, Literature Review

Fawzy¹

2015

JCPCR

View full text Add to dashboard Cite

show abstract

The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery

Cited by 132 publications

References 15 publications

The Effects of Hyperthermic Intraperitoneal Chemoperfusion on Colonic Anastomosis: An Experimental Study in a Rat Model

The Effects of Hyperthermic Intraperitoneal Chemoperfusion on Colonic Anastomosis: An Experimental Study in a Rat Model

Treatment of Peritoneal Surface Malignancies with Hyperthermic Intraperitoneal Chemotherapy—Current Perspectives

Management of Peritoneal Metastases of Colorectal Cancer, Literature Review

Contact Info

Product

Resources

About